Co-Authors
This is a "connection" page, showing publications co-authored by APOSTOLIA MARIA TSIMBERIDOU and EDMUND SCOTT KOPETZ.
Connection Strength
0.202
-
Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
Score: 0.040
-
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jul 15; 23(14):3657-3666.
Score: 0.038
-
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
Score: 0.034
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.033
-
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
Score: 0.030
-
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303.
Score: 0.027